Edesa Biotech (EDSA) Equity Income (2018)
Edesa Biotech's (EDSA) quarterly Equity Income came in at -$46456.0 in Q4 2018.
Powered by 
Analysis
Edesa Biotech (EDSA) Equity Income (2018) Analysis & Trends
Edesa Biotech has disclosed Equity Income across 1 years of filings, most recently posting -$46456.0 for Q4 2018.
- In Q4 2018, Equity Income changed N/A year-over-year to -$46456.0; the TTM figure through Mar 2019 stood at -$46456.0 (changed N/A YoY), while the FY2018 annual figure was -$20239.0, changed N/A from the prior year.
- Equity Income came in at -$46456.0 for Q4 2018 at Edesa Biotech.
- In the past five years, Equity Income ranged from a high of -$46456.0 in Q4 2018 to a low of -$46456.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Edesa Biotech | 43.87 Mn | 43.87 Mn | - | - |